Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Clinical Presentations at the ASCO 2011 Annual Meeting
WALTHAM, Mass., May 26, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at Jefferies 2011 Global Healthcare Conference
WALTHAM, Mass.--(ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Executive Vice President and CFO, Gregory Perry, will present at the
View HTML
Toggle Summary ImmunoGen, Inc. Announces Presentation of Favorable SAR3419 Interim Clinical Data at ASCO
- Novel Targeted Therapy for Non-Hodgkin's Lymphoma Demonstrates Impressive Efficacy in Early Stage Clinical Trial -
View HTML
Toggle Summary ImmunoGen, Inc. Announces Positive Clinical Data Presented on IMGN901 in the Treatment of Multiple Myeloma
- Marked Clinical Benefit Reported in Most Patients Treated -
View HTML
Toggle Summary ImmunoGen, Inc. Earns Milestone with BAY 94-9343 IND Submission
- Event triggers $2 million payment from Bayer HealthCare Pharmaceuticals -
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2011 Financial Results
WALTHAM, Mass., Jul 28, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the Company will host a conference call at 4:30 p.m.
View HTML
Toggle Summary ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2011 Financial Results and Provides Corporate Update and Fiscal Year 2012 Guidance
Company's Strong Cash Position Supports Aggressive Development of Wholly Owned Product Candidates As Partner Compounds Advance Multiple Compounds Expected to Advance to Next Stage within 12 Months
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the Canaccord Genuity 31st Annual Growth Conference
WALTHAM, Mass., Aug 05, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that its presentation at the Canaccord
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass., Aug 31, 2011 (GlobeNewswire via COMTEX) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Company management will
View HTML
Toggle Summary ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma
IMGN529 is the first IND-stage compound for non-Hodgkin's Lymphoma that provides both anticancer antibody activity and small molecule cancer-killing power
View HTML